...
首页> 外文期刊>The Journal of Antimicrobial Chemotherapy >Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables.
【24h】

Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables.

机译:格列沙星和克拉霉素清除慢性支气管炎患者痰液中潜在细菌病原体的能力比较:药代动力学和药效学变量的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

A randomized open-label study was conducted to compare the pharmacokinetics and pharmacodynamics of grepafloxacin with those of clarithromycin in patients with chronic bronchitis whose sputa were colonized with potential bacterial pathogens. Patients received oral grepafloxacin 400 mg od for 10 days (n = 15) or oral clarithromycin 500 mg bd for 10 days (n = 10). Sputum samples were collected before the first dose, 1, 4 and 8 h after a dose on day 1 and then before a dose on days 2, 3, 5, 7 and 10 to determine the time to eradication (T(erad)) of the potential bacterial pathogens. Blood samples for measurement of grepafloxacin or clarithromycin and 14-hydroxyclarithromycin concentrations were obtained before a dose and 1, 2, 4, 8 and 12 h after doses on days 1 and 5. The area under the inhibitory serum concentration-time curve over 24 h (AUIC(24)), peak serum concentration:MIC ratio (C(max):MIC) and the percentage of the dosing interval during which the serum concentration exceeded the MIC (%tau >MIC) were calculated and serum inhibitory titres (SITs) were determined. Haemophilus spp. were the predominant potential bacterial pathogens and were recovered from the sputa of 24 patients. Strains of Streptococcus pneumoniae were isolated from two patients in the grepafloxacin group and a strain of Moraxella catarrhalis was isolated from one patient in the clarithromycin group. Haemophilus spp. isolates were eradicated from the sputa of 13 of 14 (93%) patients given grepafloxacin, but from only two of 10 (20%) patients given clarithromycin (P < 0.05). In the other eight (80%) patients who received clarithromycin, the sputum cultures remained positive throughout the 10 day course. Grepafloxacin eliminated potential bacterial pathogens more quickly than clarithromycin (median T(erad) 4 h versus 76 h). The S. pneumoniae strains were eradicated by grepafloxacin within 4 h and the single M. catarrhalis strain was eradicated by clarithromycin within 1 h. The greater efficacy of grepafloxacin, compared with that of clarithromycin, in terms of the incidence and speed of eradication of the Haemophilus spp. isolates, was associated with higher median values of AUIC(24) (169 SIT(-1)*h versus 8.1 SIT(-1)*h), C(max):MIC ratio (23.6 versus 0.7) and %tau >MIC (100% versus 0%). A Hill-type model adequately described the relationship between the percentage probability of eradicating potential bacterial pathogens from sputa and the plasma grepafloxacin concentration.
机译:进行了一项随机开放标签研究,比较了格鲁帕沙星和克拉霉素对慢性支气管炎患者的药代动力学和药效学。患者接受口服口服格鲁沙星400 mg od,持续10天(n = 15),口服口服克拉霉素500 mg bd,持续10天(n = 10)。在第一次给药之前,第1天给药后的1、4和8小时,然后在第2、3、5、7和10天给药之前,采集痰样品,以确定根除时间(T(erad))潜在的细菌病原体。在给药前和给药后第1、5天,给药后1、2、4、8和12小时获得用于测量格列氟沙星或克拉霉素和14-羟基克拉霉素浓度的血样。在24小时内抑制血清浓度-时间曲线下的面积(AUIC(24)),峰值血药浓度:MIC比(C(max):MIC)和血清浓度超过MIC的给药间隔百分比(%tau> MIC),并计算血清抑制滴度(SITs) )确定。嗜血杆菌属。是主要的潜在细菌病原体,从24例患者的痰液中回收。从格列沙星组的两名患者中分离出肺炎链球菌菌株,从克拉霉素组的一名患者中分离出卡他莫拉菌菌株。嗜血杆菌属。从14例接受格列沙星的患者中有13例(93%)的痰中消灭了分离株,但是在10例(20%)的患者中使用克拉霉素的细菌中只有2例(P <0.05)。在另外八名(80%)接受克拉霉素的患者中,在整个10天的疗程中,痰培养物保持阳性。格列沙星比克拉霉素更快地消除了潜在的细菌病原体(中位T(erad)4 h比76 h)。格列沙星可在4 h内消灭肺炎链球菌,而克拉霉素可在1 h内消灭单个粘膜炎莫尔氏菌。就根除嗜血杆菌属物种的发生率和速度而言,格列氟沙星与克拉霉素相比具有更高的疗效。分离物与AUIC(24)的中位数较高有关(169 SIT(-1)* h对8.1 SIT(-1)* h),C(max):MIC比(23.6对0.7)和%tau> MIC (100%比0%)。希尔类型的模型充分描述了从痰中根除潜在细菌病原体的百分比概率与血浆格雷帕沙星浓度之间的关系。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号